Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 4, 2011

FDA Removes Liver Damage Warning from Gilead’s Pulmonary Arterial Hypertension Drug Label

  • A review of post-marketing data has led FDA to remove the liver damage warning from the prescribing information for Gilead Science’s pulmonary arterial hypertension (PAH) therapy Letairis® (ambrisentan 5 mg and 10 mg tablets). The once-daily drug has been approved in the U.S. since 2007 for helping to improve exercise ability and delay clinical worsening in PAH patients with WHO functional Class II-III symptoms. The label update means patients treated using Letairis will no longer need to undergo monthly liver function tests.

    The post-marketing data, collected through the Letairis Education and Access Program, reflected the use of ambrisentan over more than 7,800 patient years. Gilead says the data is consistent with results from the clinical trials used to support the drug’s registration. These 12-week controlled studies found the incidence of liver function abnormalities was 0% for Letrairis-treated patients and 2.3% among placebo-treated individuals.

    In its 2009 annual report Gilead suggested 200,000 people worldwide suffer from pulmonary arterial hypertension, and Letairis is used by one-third of patients receiving endothelin-receptor antagonist treatment. The firm reported Letairis sales of $64 million in the fourth quarter of 2010, up 23% on Q4 2009 figures. Sales for the 2010 year were up 31%, at $240.3 million.


Readers' Comments

Posted 03/04/2011 by Sonja Mindrebo

Yet another reminder to be cautious of prescription drug use.  THere are also dangers with over the counter medications like acetaminophen (Tylenol).  Neglecting to adhere to the recommended dosages could result in liver failure - http://www.liverfailurefromtylenol.com/ - or even death.  Just another thought.  Regards, SK.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »